A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration

NCT07718165 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

247

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor (Phase I)

Interventions

DRUG: ABSK211

Sponsor

Abbisko Therapeutics Co, Ltd